Vidipha Central Pharmaceutical JSC
HHOSE:VDP29,600.00
VND
-1,450.00
(-4.67%)
Vidipha Central Pharmaceutical JSC
HOSE:VDP
(Ho Chi Minh Stock Exchange)
Recent
price
29,600.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Vidipha Central Pharmaceutical Joint Stock Company is a Vietnam-based pharmaceutical company primarily engaged in the research, development, manufacturing, processing, trading, and distribution of generic pharmaceuticals, over-the-counter medications, health supplements, and medical supplies. The company's product portfolio spans multiple therapeutic categories and dosage forms, encompassing antibiotics and anti-infectives, including cephalosporin and penicillin formulations; analgesics, antipyretics, and non-steroidal anti-inflammatory drugs; cardiovascular, lipid-lowering, and metabolic disorder treatments; respiratory, antihistamine, and cough preparations; gastrointestinal and digestive tract medications; vitamins, minerals, and nutritional supplements; dermatological ointments, creams, and antiseptic topical solutions; and sterile injectables, lyophilized powders, tablets, film-coated tablets, hard and soft gelatin capsules, oral syrups, and dry suspensions. In addition to finished pharmaceuticals, the company distributes active pharmaceutical ingredients, functional food products, cosmetics, and disposable medical consumables, while offering contract manufacturing, toll manufacturing, and quality testing services to domestic and international pharmaceutical enterprises. Vidipha operates extensive manufacturing facilities adhering to Good Manufacturing Practice standards in Binh Duong Province, supported by certified Good Storage Practice warehouses and Good Distribution Practice logistics networks that supply public and private hospital tender channels as well as retail pharmacy chains across Vietnam. Geographically, the company also exports its formulations to regional markets, including Cambodia, Laos, Myanmar, and the Philippines, as well as select African countries. Originally established in 1976 as Central Pharmaceutical Factory No. 25 and equitized as a joint stock company in 2003, Vidipha is headquartered in Ho Chi Minh City, Vietnam. In recent operational developments, Vidipha has focused on strategic facility upgrades and production modernization, deploying capital investments to align key manufacturing lines at its Binh Duong complex with stringent European Union Good Manufacturing Practice benchmarks. The company has expanded its high-tech non-beta-lactam solid dosage and sterile injectable production lines, broadened its research and development pipeline with an emphasis on generic bioequivalence testing, and introduced newly approved high-yield therapeutic formulations. Furthermore, Vidipha has enhanced its supply chain resilience through new long-term sourcing partnerships for certified active pharmaceutical ingredients and strengthened its domestic commercial alliances to broaden its market presence across regional hospital systems and modern retail pharmacy networks.